Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Small peptides and methods for treatment of asthma and inflammation

A skin inflammation, selected technology, applied in the direction of peptides, tripeptide components, tetrapeptide components, etc., can solve the problem of inflammation without any effect

Inactive Publication Date: 2002-03-20
HISTATEK
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These therapeutics treat asthma symptoms but have no effect on the inflammation that underlies its pathogenesis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Small peptides and methods for treatment of asthma and inflammation
  • Small peptides and methods for treatment of asthma and inflammation
  • Small peptides and methods for treatment of asthma and inflammation

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0053] The compositions of the invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Methods of preparation thereof generally include the step of bringing into association the active ingredient of the invention with the carrier which constitutes one or more accessory ingredients.

[0054] Compositions of the invention suitable for administration by inhalation may be used, for example, as aerosols or solutions for inhalation. An example of a typical aerosol composition consists of the desired amount of microcrystalline peptide and oleic acid suspended in a mixture of trichlorofluoromethane and dichlorodifluoromethane. An example of a typical solution consists of the desired amount of peptide, benzalkonium chloride, and Sulfuric acid (to adjust pH) composition.

[0055] Compositions of the invention suitable for oral administration may also be presented as discrete units such as capsules, cachet...

Embodiment 1

[0070] A dose response curve of the standard compound f-Met-Leu-Phe was prepared using the selected 0.15 μg dose of compound 48 / 80. f-Met-Leu-Phe was tested at doses ranging from 0 to about 230 nM, and the results are attached figure 2 shown. The results clearly show that degranulation induced by compound 48 / 80 is inhibited.

Embodiment 2-11

[0072] The potency of several f-Met-Leu peptides to inhibit induced degranulation was determined using 100 nanomolar test peptide and 0.15 μg compound 48 / 80 in a rat skin model. For each experiment, an internal zero-peptide-dose 48 / 80 control was included for each rat, and % inhibition was expressed as a percentage relative to this control (0% inhibition). The percentage of mast cell degranulation produced by 48 / 80 was also determined. The results are listed in the table below.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

Methods for treating allergies, cutaneous inflammation, arthritis, chronic obstruction pulmonary disease and treating chronic inflammatory bowel disease are described. Also described is a method for inhibiting the infiltration of eosinophils into airways of a patient, a method for inhibiting the mucous release into airways of a patient, a method for blocking lgE activation of a lymphocyte, a method for stabillizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an lgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Try-Phe, Phe-Phe and Phe-Tyr.

Description

field of invention [0001] The present invention relates to a small peptide with mast cell degranulation inhibitory activity and a method for treating inflammation, in particular to N-formyl-methionyl peptides useful for treating the following diseases: allergies such as allergic rhinitis, urticaria, Allergies, drug allergies, and food allergies, etc., skin inflammations such as dermatitis, eczema, psoriasis, contact dermatitis, sunburn, and aging, etc., and arthritis such as osteoarthritis, psoriatic arthritis, lupus, and spondyloarthritis Wait. These peptides are also useful in the treatment of chronic obstructive pulmonary disease and chronic inflammatory bowel disease. These peptides are especially useful in place of corticosteroids in any application in which corticosteroids are used, including immunosuppression in transplantation and cancer therapy. Background of the invention [0002] Asthma is a complex disease. Genetic and environmental factors—allergies, viral in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K38/00A61K38/06A61K38/07A61K38/35A61K45/00A61P1/04A61P11/00A61P17/00A61P17/04A61P17/06A61P17/16A61P19/02A61P27/16A61P35/00A61P37/06A61P37/08A61P43/00C07K5/083C07K5/103
CPCA61K38/06A61K38/07A61P1/04A61P11/00A61P17/00A61P17/04A61P17/06A61P17/16A61P19/02A61P27/16A61P35/00A61P37/06A61P37/08A61P43/00A61K38/00
Inventor J·C·胡克J·克拉盖特
Owner HISTATEK
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com